Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.77 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.77 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.77 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.77 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.77 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.77 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.77 |
| ▸ | CPN1 | P15169 | 2/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225755 | 1.00 | SLC6A1 (0.77) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL18828823 | 1.00 | SLC6A1 (0.77) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL5050450 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL22323200 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL4115452 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL27564309 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL15550547 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Acetic Acid SCHEMBL28794935 | 0.94 | SLC6A1 (0.69) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL5501438 | 0.94 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Trifluoroacetic Acid SCHEMBL4096831 | 0.89 | SLC6A1 (0.62) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116669727-A | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists | 唯久生物有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20200399634-A1 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399634-A1 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| WO-2019168654-A9 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| WO-2017190048-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | X-CHEM, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| CN-102933572-B | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2015-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | SLC6A1 3608/4885SLC6A11 3584/4885SLC6A13 3876/4885 |
| US-20200399634-A1 | DNA-TEMPLATED MACROCYCLE LIBRARY | IDE, IAPP, POLRMT | SLC6A1 3608/4885SLC6A11 3584/4885SLC6A13 3876/4885 |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | SLC6A1 1017/4885SLC6A11 1014/4885SLC6A13 1565/4885 |
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | SLC6A1 2024/4885SLC6A11 2444/4885SLC6A13 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.